EGFR and head and neck squamous cell carcinoma: In 2006, cetuximab, a chimeric monoclonal antibody against EGFR, was announced by the United States Food and Drug Administration (the FDA) to be approved for use in HNSCC (Head and Neck Squamous Cell Carcinoma) patients (Cohen, 2014).